T Kuittinen
Overview
Explore the profile of T Kuittinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tulokas S, Mentula M, Harkki P, Brummer T, Jalkanen J, Kuittinen T, et al.
Arch Gynecol Obstet
. 2022 Jan;
305(4):1089-1097.
PMID: 35061067
Purpose: Hysterectomy has been associated with increased risk for developing stress urinary incontinence (SUI) and having a SUI operation. We examined the long-term rate of SUI operations after hysterectomy and...
2.
Silvennoinen R, Anttila P, Saily M, Lundan T, Heiskanen J, Siitonen T, et al.
Bone Marrow Transplant
. 2015 Oct;
51(3):372-6.
PMID: 26437056
The most common means of mobilizing autologous stem cells is G-CSF alone or combined with cyclophosphamide (CY) to obtain sufficient CD34+ cells for one to two transplants. There are few...
3.
Husso M, Sipola P, Kuittinen T, Manninen H, Vainio P, Hartikainen J, et al.
Physiol Meas
. 2014 Mar;
35(4):533-47.
PMID: 24577344
Quantification of regional myocardial blood flow (rMBF) with first-pass magnetic resonance imaging (FP-MRI) requires two contrast agent injections (dual bolus technique), inducing error in the determined rMBF if the injections...
4.
Varmavuo V, Mantymaa P, Kuittinen T, Nousiainen T, Jantunen E
Transfus Apher Sci
. 2012 Apr;
46(3):257-62.
PMID: 22465758
Background: CXCR4 receptor antagonist plerixafor is used to mobilize hematopoietic stem cells. No detailed data regarding the effects of plerixafor on other blood cell components have been published but may...
5.
Jantunen E, Varmavuo V, Juutilainen A, Kuittinen T, Mahlamaki E, Mantymaa P, et al.
Ann Hematol
. 2012 Feb;
91(7):1073-9.
PMID: 22302373
Mobilization and collection of stem cells is difficult in a proportion of patients intended for autologous stem cell transplantation (ASCT). We have evaluated mobilization kinetics of blood CD34(+) cells (B-CD34(+))...
6.
Jantunen E, Penttila K, Pyorala M, Mahlamaki E, Kuittinen T, Nousiainen T
Bone Marrow Transplant
. 2010 Apr;
46(2):308-9.
PMID: 20400986
No abstract available.
7.
Hamalainen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E
Scand J Infect Dis
. 2008 Oct;
41(1):14-20.
PMID: 18836947
Infectious complications are the main reason for early treatment-related mortality after autologous stem cell transplantation (ASCT). We evaluated retrospectively microbiological aetiology, risk factors and clinical consequences of severe sepsis in...
8.
Jantunen E, Itala M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, et al.
Bone Marrow Transplant
. 2007 Oct;
41(3):239-44.
PMID: 17968327
Some reports suggest that blood stem cell mobilization is difficult in a proportion of patients with CLL. We evaluated this issue in a large cohort of CLL patients. One hundred...
9.
Jantunen E, Heinonen K, Mahlamaki E, Penttila K, Kuittinen T, Lehtonen P, et al.
Leuk Lymphoma
. 2007 Feb;
48(1):190-1.
PMID: 17325866
No abstract available.
10.
Kuittinen T, Jantunen E, Vanninen E, Mussalo H, Vuolteenaho O, Ala-Kopsala M, et al.
Eur J Haematol
. 2006 Jul;
77(2):120-7.
PMID: 16856907
Objectives: Limited data are available on the cardiac effects of high-dose cyclophosphamide (CY) in patients with non-Hodgkin's lymphoma (NHL). We prospectively assessed the cardiac effects of high-dose CY in 30...